Chemotherapy for prostate cancer : implementing early systemic therapy to improve outcomesMACVICAR, Gary R; HUSSAIN, Maha.Cancer chemotherapy and pharmacology. 2005, Vol 56, issn 0344-5704, s69-s77, SUP1Article

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II national cancer institute trialHUSSAIN, Maha H. A; MACVICAR, Gary R; CHEN, Helen et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2218-2224, issn 0732-183X, 7 p.Article

A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial CarcinomaHUSSAIN, Maha; DAIGNAULT, Stephanie; EISENBERGER, Mario A et al.Cancer. 2014, Vol 120, Num 17, pp 2684-2693, issn 0008-543X, 10 p.Article

Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy programSHAH, Rajal B; MEHRA, Rohit; KIM, Robert et al.Cancer research (Baltimore). 2004, Vol 64, Num 24, pp 9209-9216, issn 0008-5472, 8 p.Article

Phase I/II Trial of Orteronel (TAK-700)―an Investigational 17,20-Lyase Inhibitor―in Patients with Metastatic Castration-Resistant Prostate CancerDREICER, Robert; MACLEAN, David; YUANJUN SHI et al.Clinical cancer research (Print). 2014, Vol 20, Num 5, pp 1335-1344, issn 1078-0432, 10 p.Article